Rational design, synthesis, and serine protease inhibitory activity of novel P1-argininoyl heterocycles

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 10, 1997, Pages 1359-1364

  Tamura, Susan Y ^a   Shamblin, Brian M ^a   Brunck, Terence K ^a   Ripka, William C ^a  

^a Dendreon   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOXAZOLE DERIVATIVE; BLOOD CLOTTING FACTOR 10A; DIPEPTIDE; PLASMIN; PROTHROMBIN A; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THROMBIN;

ARTICLE; DRUG DESIGN; DRUG PURIFICATION; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MOLECULAR MODEL;

EID: 0031579958     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(97)00227-8     Document Type: Article

References (34)

1. Coleman, R.W.; Marder, V.J.; Salzman, E.W.; Hirsch, J. Hemostasis and Thrombosis, Basic Principles and Clinical Practice; 3rd ed.; Colman, R.W.; Hirsch, J.; Marder, V.J.; Salzman, E.W.; Eds.; J.B. Lippincott: Philadelphia, 1994; Chapters 1, 9, 57, and 80-86.
2. (a) Bazan, J.F. Nature 1996, 380, 21.
3. (b) Tapparelli, C.; Meternich, R.; Ehrhardt, C.; Cook, N.S. TIPS 1993, 14, 366.
4. (c) Maraganore, J.M. Thromb. Haemostasis 1993, 70, 208-211.
5. (d) Tans, G.; Rosing, J.; Thomassen, M.C.; Heeb, M.J.; Zwaal, R.F.; Griffin, J.H.; Blood 1991, 77, 2641.
6. (a) Hilpert, K.; Ackermann, J.; Banner, D.W.; Gast, A.; Gubernator, K.; Hadvary, P.; Labler, L.; Muller, K.; Schmid, G.; Tshopp, T.B.; van de Waterbeemd, H. J. Med. Chem. 1994, 37, 3889.
7. (b) Topol, E.J.; Bonan, R.; Jewitt, D.; Sigwart, U.; Kakkar, V.V.; Rothman, M.; de Bono, D.; Fegurson, J.; Willerson, J.T.; Strony, J.; Ganz, P.; Cohen, M.D.; Raymond, R.; Fox, I.; Maranganore, J.; Adelman, B. Circulation 1993, 87, 1622.
8. (c) Powers, J.C.; Kam, C.M. Thrombin: Structure and Function; Berliner, L.J., Ed.; Plenum: New York, 1992; pp 117-158.
9. (d) Lyle, T.A.; Perspectives in Drug Discovery and Design 1993, 1, 453.
10. (e) Scarborough, R.M. In Ann. Rep. Med. Chem.; Bristol, J.A. Ed.; Academic: San Diego, 1995; Vol. 30, pp 71-80.
11. (f) Harker, L.A.; Hanson, S.R.; Kelly, A.B. Thromb. Haemost. 1995, 74, 464.
12. Edwards P.D., Meyer E.F. Jr., Vijayalakshmi J., Tuthill P.A., Andisik D.A., Gomes B., Strimpler A. J. Am. Chem. Soc. 114:1992;1854.
13. (a) Edwards, P.D.; Wolanin, D.J.; Andisik, D.W.; Davis, M.W. J. Med. Chem. 1995, 38, 76.
14. (b) Edwards, P.D.; Zotall, M.A.; Davis, M.W.; Williams, J.; Tuthill, P.A. J. Med. Chem. 1995, 38, 3972.
15. Tsutsumi S., Okonogi T., Shibahara S., Ohuchi S., Hatsushiba E., Patchett A.A., Christensen B.G. J. Med. Chem. 37:1994;3492.
16. Costanzo M.J., Maryanoff B.E., Hecker L.R., Schott M.R., Yabut S.C., Zhang H.-C., Andrade-Gordon P., Kauffman J.A., Lewis J.M., Krishnan R., Tulinsky A. J. Med. Chem. 39:1996;3039.
17. Brunck, T.K.; Webb, T.R.; Ripka, W.C.; European Patent Application, WO 94/13693, 1994.
18. (a) Morgan, B.A.; Gainor, J.A. In Ann. Rep. Med. Chem.; Allen, R.C., Ed.; Academic: San Diego, 1989; Vol. 24, Chapter 26, pp 243-252.
19. (b) Spatola, A.F. in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins; Weinstein, B., Ed.; Marcel Dekker: New York, 1983; Vol. 7, Chapter 5.
20. (c) Rich, D.H. in Comprehensive Medicinal Chemistry. Hansch, C.; Sammes, G.; Taylor, J.B.; Eds.; Pergamon: Oxford, 1990; Vol. 2, Chapter 8.
21. All new compounds were characterized by full spectroscopic (NMR, IR, low/high-resolution MS) data. Yields refer to spectroscopically and chromatographically homogeneous (≥95% by 1H NMR, HPLC, TLC) materials.
22. Attempts to convert t-butylacetyl-dPhePro-nitroargininal cyanohydrin to the corresponding peptidoyl benzoxazole via the imidate employing the standard protocol were unsuccessful in our laboratory.
23. Boc Ng-nitroargininal 5 was prepared according to a modified procedure of Goel et al. NMR and HPLC analyses indicate that 5 exists as a mixture of the two cyclic hemiaminal forms and the free aldehyde.
24. Goel O.P., Krolls U., Stier M., Kesten S. Organic Syntheses. 67:1988;69.
25. This mixture of stereosiomers was carried forward through the synthesis. The stereochemistry becomes irrelevant due to the loss of the stereocenter during the oxidation to the ketone at the last step.
26. (a) Wagner, G.; Horn, H.; Richter, P.; Vieweg, H.; Lischke, I.; Kazmirowski, H.-G. Pharmazie 1981, 36, 597.
27. (b) For the description of the reaction of thioimidates with 2-amino-3-hydroxypyridine, see Doise, M.; Blondeau, D.; Sliwa, H. Synth. Commun. 1992, 22, 2891.
28. (c) For the description of the reaction of acetic acid thioimidate with o-aminophenol to give 2-methylbenzoxazole, see El Khadem, H.S.; Kawai, J. Carbohydr. Res. 1986, 153, 271.
29. For a detailed experimental procedure describing the preparation of compound 8, see Webb, T.R.; Miller, T.A.; Vlasuk, G.P. US Patent 5,371,072, 1994; Chem. Abstr. 1997, 126, 199831.
30. For a detailed experimental procedure describing the preparation of compound 8, see Webb, T.R.; Miller, T.A.; Vlasuk, G.P. US Patent 5,371,072, 1994; Chem. Abstr. 1997, 126, 199831.
31. Mono-Boc phenylene diamine was prepared by the treatment of phenylenediamine, dihydrochloride salt, with one equiv Boc anhydride and three equiv sodium bicarbonate in aqueous dioxane. Recrystallization of the crude product from ethyl acetate/hexanes provided the desired product, which was spectroscopically and chromatographically homogeneous (≥95% by 1H NMR, and TLC).
32. t-Butylacetyl-dPheProOH and Ac-dPheProOH, prepared using standard solution phase peptide coupling techniques, were spectroscopically and chromatographically homogeneous (≥95% by 1H NMR, and TLC).
33. In vitro enzyme assays were performed according to the protocols described in the following article: Semple, J.E.; Rowley, D.C.; Brunck, T.K.; Ha-Uong, T.; Minami, N.K.; Owens, T.D.; Tamura, S. Y.; Goldman, E.A.; Siev, D.V.; Ardecky, R.A.; Carpenter, S.H.; Ge, Y.; Richard, B.M.; Nolan, T. G.; H̊akanson, K.; Tulinsky, A.; Nutt, R.F.; Ripka, W.C. J. Med. Chem. 1996, 39, 4531.
34. The crystal structure of PPACK-thrombin was elucidated by Vijayalakshmi, J.; Padmanabhan, K.P.; Mann, K.G.; Tulinsky, A. Protein Sci. 1994, 3, 2254, and was used with the computer programs Insight II and Discover (MSI, San Diego, CA) to model and display the inhibitors.